Legend Biotech says Carvykti myeloma study met primary endpoint

Legend Biotech announced that CARTITUDE-4, the Phase 3 study evaluating Carvykti for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma, met its primary endpoint of showing a statistically significant improvement in progression-free survival compared to standard therapy at the study’s first pre-specified interim analysis. The study has been unblinded following the recommendation of an independent data monitoring committee. The study is evaluating the efficacy and safety of a CAR-T therapy versus pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone in adult patients with relapsed and lenalidomide-refractory multiple myeloma who received one to three prior lines of therapy. Results from the CARTITUDE-4 study will be submitted to an upcoming medical meeting and will support discussions with health authorities about potential regulatory submissions, Legend said in a statement. The stock is up 4% to $56.16 in premarket trading.